Published in Cancer Res on April 21, 2009
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77
Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One (2009) 2.36
What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol (2012) 1.42
Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res (2009) 1.39
The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS One (2013) 1.22
Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J Clin Endocrinol Metab (2012) 1.21
Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res (2013) 1.19
Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets. J Immunol Methods (2011) 1.15
Bone marrow and the control of immunity. Cell Mol Immunol (2011) 1.15
IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest (2014) 1.12
Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. Oncoimmunology (2012) 1.08
Development of a nascent galectin-1 chimeric molecule for studying the role of leukocyte galectin-1 ligands and immune disease modulation. J Immunol (2010) 1.04
The intratumoural subsite and relation of CD8(+) and FOXP3(+) T lymphocytes in colorectal cancer provide important prognostic clues. Br J Cancer (2014) 1.02
Regulatory and activated T cells in human Schistosoma haematobium infections. PLoS One (2011) 1.02
Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer. Chin J Cancer Res (2012) 1.01
Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice. Cancer Res (2012) 1.01
The pathogen recognition receptor NOD2 regulates human FOXP3+ T cell survival. J Immunol (2010) 1.00
Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization. Clin Dev Immunol (2011) 0.97
T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies. Immunology (2010) 0.96
Rational combinations of immunotherapeutics that target discrete pathways. J Immunother Cancer (2013) 0.95
The role of regulatory T cells in cancer. Immune Netw (2009) 0.93
Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer. Front Immunol (2013) 0.91
The phenotypic and functional consequences of tumour necrosis factor receptor type 2 expression on CD4(+) FoxP3(+) regulatory T cells. Immunology (2011) 0.90
Pathway-based analysis of a melanoma genome-wide association study: analysis of genes related to tumour-immunosuppression. PLoS One (2011) 0.88
Mechanisms of immune response regulation in lung cancer. Transl Lung Cancer Res (2014) 0.86
FOXP3 gene polymorphism is associated with hepatitis B-related hepatocellular carcinoma in China. J Exp Clin Cancer Res (2013) 0.86
Predictors of immunosuppressive regulatory T lymphocytes in healthy women. J Cancer Epidemiol (2012) 0.86
Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther (2015) 0.85
Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression. Oncoimmunology (2014) 0.84
Utilizing regulatory T cells against rheumatoid arthritis. Front Oncol (2014) 0.83
The peroxisome-proliferator activated receptor-γ agonist pioglitazone modulates aberrant T cell responses in systemic lupus erythematosus. Clin Immunol (2013) 0.83
Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies. Cancers (Basel) (2010) 0.83
Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma. Contemp Oncol (Pozn) (2015) 0.83
Role played by CD4+FOXP3+ regulatory T Cells in suppression of host responses to Haemophilus ducreyi during experimental infection of human volunteers. J Infect Dis (2010) 0.83
Increased numbers of gastric-infiltrating mast cells and regulatory T cells are associated with tumor stage in gastric adenocarcinoma patients. Oncol Lett (2012) 0.82
Considerations for successful cancer immunotherapy in aged hosts. Clin Exp Immunol (2016) 0.81
Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type. Int J Mol Sci (2016) 0.80
Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis. BMC Cancer (2016) 0.79
Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients. Tumour Biol (2015) 0.79
The numbers of FoxP3+ lymphocytes in sentinel lymph nodes of breast cancer patients correlate with primary tumor size but not nodal status. Cancer Invest (2011) 0.79
The tumor area occupied by Tbet+ cells in deeply invading cervical cancer predicts clinical outcome. J Transl Med (2015) 0.79
Inflammatory regulatory T cells in the microenvironments of ulcerative colitis and colon carcinoma. Oncoimmunology (2016) 0.78
Regulatory T cells in peripheral blood, lymph node, and thyroid tissue in patients with medullary thyroid carcinoma. World J Surg (2010) 0.78
Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients. Sci Rep (2016) 0.77
Morphometric analysis of the balance between CXCR3+ T cells and FOXP3+ regulatory T cells in lymphocyte-rich and conventional gastric cancers. Virchows Arch (2010) 0.77
High immunosuppressive burden in advanced hepatocellular carcinoma patients: Can effector functions be restored? Oncoimmunology (2013) 0.76
Dissecting the regulatory microenvironment of a large animal model of non-Hodgkin lymphoma: evidence of a negative prognostic impact of FOXP3+ T cells in canine B cell lymphoma. PLoS One (2014) 0.76
Blockade of TNF-α signaling benefits cancer therapy by suppressing effector regulatory T cell expansion. Oncoimmunology (2015) 0.76
Impact of autoimmune diseases on outcome of patients with early breast cancer. Oncotarget (2016) 0.75
Glycyrrhiza uralensis water extract enhances dendritic cell maturation and antitumor efficacy of HPV dendritic cell-based vaccine. Sci Rep (2017) 0.75
Preliminary study on decreasing the expression of FOXP3 with miR-155 to inhibit diffuse large B-cell lymphoma. Oncol Lett (2017) 0.75
Cancer-FOXP3 directly activated CCL5 to recruit FOXP3(+)Treg cells in pancreatic ductal adenocarcinoma. Oncogene (2016) 0.75
Group III phospholipase A2 promotes colitis and colorectal cancer. Sci Rep (2017) 0.75
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80
Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood (2009) 4.13
Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol (2007) 3.81
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med (2006) 3.75
Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol (2008) 3.22
Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes Dev (2011) 3.05
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene (2002) 2.81
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol (2009) 2.66
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol (2009) 2.53
Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol (2006) 2.50
CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res (2005) 2.38
Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol (2006) 2.36
Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev (2011) 2.30
Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res (2004) 2.28
c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology (2011) 2.27
Helicobacter pylori immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. Gastroenterology (2009) 2.22
Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J Immunol (2007) 2.21
Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res (2005) 2.06
Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays. Nat Methods (2007) 2.06
Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer (2011) 2.05
Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res (2007) 2.01
Human TH17 cells are long-lived effector memory cells. Sci Transl Med (2011) 1.99
Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol (2005) 1.96
Regulatory T-cell compartmentalization and trafficking. Blood (2006) 1.86
BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res (2006) 1.85
NF-kappaB activation in pancreas induces pancreatic and systemic inflammatory response. Gastroenterology (2002) 1.84
Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol (2008) 1.79
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol (2013) 1.79
Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity (2013) 1.77
IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer. J Immunol (2011) 1.76
Deciphering the role of Th17 cells in human disease. Trends Immunol (2011) 1.76
RAMPing up the quality of rectal cancer surgery. J Clin Oncol (2014) 1.70
Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res (2007) 1.66
Th17 cells in cancer: help or hindrance? Carcinogenesis (2011) 1.63
SATB1 is an independent prognostic marker for gastric cancer in a Chinese population. Oncol Rep (2010) 1.56
Diffuse alveolar hemorrhage induced by sevoflurane. Ann Am Thorac Soc (2014) 1.48
Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology (2012) 1.47
Computed tomographic colonography for patients at high risk of colorectal cancer: trading accuracy for access and compliance. JAMA (2009) 1.39
Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res (2009) 1.39
Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. Cancer Res (2008) 1.38
Expression of SATB1 and heparanase in gastric cancer and its relationship to clinicopathologic features. APMIS (2010) 1.37
NF-κB inhibits osteogenic differentiation of mesenchymal stem cells by promoting β-catenin degradation. Proc Natl Acad Sci U S A (2013) 1.35
Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res (2004) 1.35
Dual biological effects of the cytokines interleukin-10 and interferon-γ. Cancer Immunol Immunother (2011) 1.34
Optical spectroscopy detects histological hallmarks of pancreatic cancer. Opt Express (2009) 1.33
The Tim-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft. Cell Immunol (2008) 1.31
Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma. Am J Clin Nutr (2013) 1.29
A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics Clin Appl (2011) 1.25
Prognostic significance of regulatory T cells in tumor. Int J Cancer (2010) 1.24
Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Front Biosci (Landmark Ed) (2009) 1.23
Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res (2011) 1.22
Activation of Tim-3-Galectin-9 pathway improves survival of fully allogeneic skin grafts. Transpl Immunol (2008) 1.21
Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry. J Proteome Res (2010) 1.20
Accurate molecular classification of human cancers based on gene expression using a simple classifier with a pathological tree-based framework. Am J Pathol (2003) 1.20